An Endothelial Address for the Sphingosine 1-Phosphate Axis: Cell-Type Attribution of 171 Sphingolipid Targets Across 27 Human Cancers
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27219604 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Tunan Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. Hauptthemen laut MEDLINE: Sphingosine, Lysophospholipids, Neoplasms, Sphingolipids. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Commission Capacity Building and Continuing Education Center, Beijing University of Chinese Medicine, Capacity Building and Continuing Education Center of the National Health Commission.
Abstract (Originalsprache)
Sphingolipid enzymes have been nominated as cancer targets for three decades. Six pathway genes are the target of an approved drug, with every approval being for multiple sclerosis, ulcerative colitis, or a lysosomal storage disease, and none for cancer. We defined a cell-type attribution index (CTAI) placing each gene on an axis from the malignant compartment to the microenvironment, computed it from compartment means in pan-cancer tumour single-cell data, reproduced it in proteomic and spatial data, and crossed it with cell-line dependency. CTAI reproduces at Spearman +0.30 against the protein index and +0.50 against the spatial one. S1PR1 and SPNS2 rank endothelium first in 23 of 31 and 22 of 31 datasets. Normal tissue immune fraction declines as CTAI rises (ρ = −0.52 core set, −0.60 genome-wide). Modelability, the proportion of genes yielding a dependency model that meets the predictability criterion, falls across the four functional groups (Cochran–Armitage p = 0.0024). Matched control genes fall the same way (p = 7.9 × 10−7), indicating that the gradient is not specific to sphingolipids. Clinical-stage targets sit in the low-attribution, low-dependency quadrant of our set, but genome-wide, with the target development level and literature volume held constant, that quadrant carries no advantage (odds ratio 1.05, 95% confidence interval 0.89 to 1.24). Attribution splits this pathway into a cell-autonomous arm, which cell-line dependency screens measure directly, and a sphingosine 1-phosphate arm expressed mostly outside the malignant compartment, in cells those screens do not contain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
- School of Management, Beijing University of Chinese Medicine, Beijing 102488, China.
ORCID-Profile: Weishu Li, Youting Yi
Förderung
- National Health Commission Capacity Building and Continuing Education Center
- Beijing University of Chinese Medicine
- Capacity Building and Continuing Education Center of the National Health Commission
Zitieren
APA
Ding, T., Li, W., Yi, Y., Fan, X., Tan, J., Han, A., & Tang, Y. (2026). An Endothelial Address for the Sphingosine 1-Phosphate Axis: Cell-Type Attribution of 171 Sphingolipid Targets Across 27 Human Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219604
Vancouver
Ding T, Li W, Yi Y, Fan X, Tan J, Han A, et al. An Endothelial Address for the Sphingosine 1-Phosphate Axis: Cell-Type Attribution of 171 Sphingolipid Targets Across 27 Human Cancers. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219604
BibTeX
@article{Ding2026,
author = {Ding, Tunan and Li, Weishu and Yi, Youting and Fan, Xuan and Tan, Jiahao and Han, Aiqing and Tang, Yan},
title = {An Endothelial Address for the Sphingosine 1-Phosphate Axis: Cell-Type Attribution of 171 Sphingolipid Targets Across 27 Human Cancers},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27219604}
}
EUVIMED